Cancer Stem Cell News Volume 9.37 | Sep 30 2020







2020-09-30 | CSCN 9.37


Cancer Stem Cell News by STEMCELL Technologies
Vol. 9.37 – 30 September, 2020
TOP STORY

DCLK1, a Putative Novel Stem Cell Marker in Human Cholangiocarcinoma

Investigators evaluated in vitro the expression and the biological function of DCLK1 in intrahepatic cholangiocarcinom (CCA) and perihilar CCA.
[Hepatology]

Abstract

How have LSCs changed our understanding of myeloid malignancies? Webinar by Dr. Christopher Park, NYU
PUBLICATIONSRanked by the impact factor of the journal

ATR
Is Essential for Preservation of Cell Mechanics and Nuclear Integrity during Interstitial Migration

ATR-defective cells were defective in neuronal migration during development and in metastatic dissemination from circulating tumor cells.
[Nature Communications]

Full Article

The
Cross-Talk between Methylation and Phosphorylation in Lymphoid-Specific Helicase Drives Cancer Stem-Like Properties

The arginine methyltransferase PRMT5 can methylate lymphoid-specific helicase (LSH) at R309 residue, meanwhile, LSH could as well be phosphorylated by MAPK1 kinase at S503 residue.
[Signal Transduction and Targeted Therapy]

Full Article

In Vitro
Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy

Scientists performed BSH-polyR-based boron neutron capture therapy (BNCT) against glioma stem-like cells and revealed that BSH-polyR successfully induced BNCT-dependent cell death specifically in CD44High cells.
[Cells]

Full Article

Upregulation of S100A10 in Metastasized Breast Cancer Stem Cells

Knockdown of S100A10 in breast cancer cells suppressed and overexpression of S100A10 in breast cancer patient‐derived tumor xenograft cells enhanced their invasion abilities and 3D organoid formation capacities in vitro.
[Cancer Science]

Abstract

Downregulation
of the CCL2/CCR2 and CXCL10/CXCR3 Axes Contributes to Antitumor Effects in a Mouse Model of Malignant Glioma

Scientists studied the importance of paracrine signaling in the glioma microenvironment by focusing on the celecoxib-mediated role of chemokines C–C motif ligand 2, C-X-C ligand 10, and their receptors, CCR2 and CXCR3, in glioma stem cells (GSCs) and a GSC-bearing malignant glioma model.
[Scientific Reports]

Full Article

6-Methoxymellein Isolated from Carrot (Daucus carota
L.) Targets Breast Cancer Stem Cells by Regulating NF-κB Signaling

Investigators isolated the compound 6-methoxymellein, which inhibits the proliferation and migration of breast cancer cells, reduces mammosphere growth, decreases the proportion of CD44+/CD24 cells in breast cancer cells and decreases the expression of stemness-associated proteins c-Myc, Sox-2 and Oct4.
[Molecules]

Full Article

Integrative
Analysis of the Common Genetic Characteristics in Ovarian Cancer Stem Cells Sorted by Multiple Approaches

Researchers collected the gene expression profiles of ovarian (O)CSCs were from five public cohorts and employed R software and Bioconductor packages to establish differently expressed genes between OCSCs and parental cells.
[Journal of Ovarian Research]

Full Article

Tumor-Associated
Macrophages Derived from Cancer Stem Cells

Human induced pluripotent stem cells were converted into CSCs in the presence of conditioned medium from PK8 cells. CSCs were then transplanted in vivo and formed primary tumors.
[Acta Histochemica]

Full Article

Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.
REVIEWS

Critical Role of HOX Transcript Antisense Intergenic RNA (HOTAIR)
in Gliomas

The authors provide evidence on the functional role of HOX transcript antisense intergenic RNA (HOTAIR) in gliomas and discuss the benefits of its targeting as a novel approach toward glioma treatment.
[Journal of Molecular Medicine]

Abstract
INDUSTRY AND POLICY NEWS

Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase III Bridging Study in Acute Myeloid Leukemia

Apollomics, Inc. announced APL-106 has received Investigational New Drug approval from the China National Medical Products Administration Center for Drug Evaluation. This approval enables the initiation of a Phase I pharmacokinetic and tolerability study and includes acceptance of a Phase III bridging study of APL-106 in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.
[Apollomics, Inc.]

Press Release

Basilea
Initiates Targeted Biomarker-Driven Phase II Study with Lisavanbulin in Patients with Brain Cancer

Basilea Pharmaceutica Ltd. announced that it has initiated a Phase II expansion study with its tumor checkpoint controller, lisavanbulin, in patients with recurrent glioblastoma multiforme, whose tumor has tested positive for the potential response-predictive biomarker end-binding protein 1.
[Basilea Pharmaceutica Ltd. ]

Press Release
FEATURED EVENT

San Antonio Breast Cancer Symposium

Dec 8 – Dec 12, 2020
Virtual

> See All Events

JOB OPPORTUNITIES

Research Fellow – Pancreatic and Liver Cancers

The Mayo Clinic – Jacksonville, Florida, United States


Postdoctoral Fellow – Stem Cells and Cancer

Albert Einstein College of Medicine – New York, New York, United States

Assistant/Associate
Professor – Center for Molecular Medicine

The University of Georgia – Athens, Georgia, United States


Postdoctoral Position – Cancer Stem Cell Biology

Karolinska Institute – Solna, Sweden

Postdoctoral Position – Human Pluripotent Stem Cells, Hematopoiesis and Leukemia

Icahn School of Medicine at Mount Sinai – New York City, New York, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Science News Cancer Stem Cell News
Archives Contact Us
Cancer Stem Cell News Twitter


0
Share